Anzeige
Erschienen in:
18.05.2021 | Original Article
Liver Fibrosis in the Natural Course of Chronic Hepatitis B Viral Infection: A Systematic Review with Meta-Analysis
Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2022
Einloggen, um Zugang zu erhaltenAbstract
Background
Quantitative data are limited on the natural course of liver fibrosis in patients with chronic HBV infection (CHB).
Aims
To estimate the prevalence of fibrosis status including non-fibrosis, significant fibrosis, advanced fibrosis, and cirrhosis throughout the natural course of CHB.
Methods
We searched Cochrane library, EMBASE, PubMed, SCOPUS, Web of Science, and ScienceDirect from January 1993 to November 2019 for studies with histologic data on liver fibrosis in CHB natural course. CHB course was defined based on current criteria for identifying infection phases as recommended by international clinical practice guidelines, including the HBeAg-positive immune-tolerant, HBeAg-positive immune-active, HBeAg-negative immune-inactive, HBeAg-negative immune-reactive, and HBsAg-negative phases. Pooled prevalence rate of fibrosis status at each phase was obtained from random-effect meta-analyses.
Results
Thirty-three studies with 9,377 adult participants (23.8–49.0 age years; 45.5–88.6% males) were eligible and finally included. The estimated prevalence of non-fibrosis, significant fibrosis, advanced fibrosis, and cirrhosis was, for HBeAg-positive immune-tolerant phase: 31.2% (95%CI 15.6–46.7), 16.9% (95%CI 7.8–26.1), 5.4% (95%CI 0.0–11.2), and 0.0% (95%CI 0.0–1.5); HBeAg-positive immune-active phase: 6.9% (95%CI 3.6–10.2), 50.6% (95%CI 39.2–61.9), 32.1% (95%CI 24.2–40.0), and 12.8% (95%CI 8.6–17.0); HBeAg-negative immune-inactive phase: 32.4% (95%CI 0.0–100.0), 24.8% (95%CI 4.5–45.1), 3.0% (95%CI 0.0–8.3), and 0.0% (95%CI 0.0–1.0); and HBeAg-negative immune-reactive phase: 6.3% (95%CI 3.5–9.2), 50.3% (95%CI 38.9–61.7), 30.3% (95%CI 20.9–39.6), and 10.0% (95%CI 6.6–13.5), respectively. There was only one study for HBsAg-negative phase, thus not allowing further meta-analyses.
Conclusions
Fibrosis risk persists through CHB natural course. These data can support risk estimation in clinical practice and provide reference for noninvasive investigation.